智飞生物(300122.SZ)：冻干水痘灭活疫苗获得临床试验批准通知书

Core Viewpoint - The company, Zhifei Biological, has received approval from the National Medical Products Administration for clinical trials of its lyophilized inactivated varicella vaccine, which aims to prevent chickenpox caused by the varicella-zoster virus [1] Group 1 - The lyophilized inactivated varicella vaccine is developed by the company's wholly-owned subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. [1] - The vaccine utilizes an innovative inactivation technology route, with both the production cell lines and strains being independently developed by the company [1] - The product demonstrates significant safety advantages and is suitable for individuals aged 12 months and older, providing a safer vaccination option for both healthy individuals and those with immune deficiencies or contraindications [1] Group 2 - The approval for clinical trials represents a result of the company's focus on innovative technology and strengthening core competencies [1] - If the project progresses smoothly, it will further enrich the company's upgraded vaccine varieties, enhance its product portfolio, and strengthen its market position [1]